1. Search Result
Search Result
Results for "

ischemia–reperfusion

" in MedChemExpress (MCE) Product Catalog:

121

Inhibitors & Agonists

1

Biochemical Assay Reagents

14

Peptides

2

Inhibitory Antibodies

23

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W006566

    5-Aminoisoquinolin-1-one

    PARP Cancer
    5-AIQ (5-Aminoisoquinolin-1-one) is a water-soluble PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver .
    5-AIQ
  • HY-141625

    HIF/HIF Prolyl-Hydroxylase Others
    TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury .
    TRC160334
  • HY-101205

    Opioid Receptor Cardiovascular Disease
    ICI 199441 is a potent and selective κ-opioid receptor agonist. ICI 199441 can improve heart resistance to ischemia/reperfusion .
    ICI 199441
  • HY-W015061
    Phenylacetylglycine
    1 Publications Verification

    Adrenergic Receptor Apoptosis Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion .
    Phenylacetylglycine
  • HY-B0079

    Org25969

    Others Cardiovascular Disease Neurological Disease Cancer
    Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury .
    Sugammadex sodium
  • HY-122005

    NO Synthase Inflammation/Immunology
    AVE-9488 is an eNOS enhancer with the activity of protecting the heart from ischemia-reperfusion injury. AVE-9488 can upregulate eNOS expression, increase NO production, reduce myocardial ischemia-reperfusion injury, and reduce the level of reactive oxygen species .
    AVE-9488
  • HY-119909

    Mitochondrial Metabolism Cardiovascular Disease
    GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo .
    GNX-865
  • HY-141625A

    HIF/HIF Prolyl-Hydroxylase Others
    TRC160334 sodium is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 sodium can be used for the research of ischemia/reperfusion injury .
    TRC160334 sodium
  • HY-119955

    LY-141894

    Xanthine Oxidase Others
    Amflutizole (LY-141894) is an inhibitor of xanthine oxidase. Amflutizole abolishes free radical formation and release in cerebral ischemia/reperfusion mice .
    Amflutizole
  • HY-B0079A

    Org25969 free acid

    Others Cardiovascular Disease Neurological Disease Cancer
    Sugammadex is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex shows nephroprotective effect in ischemia-reperfusion injury .
    Sugammadex
  • HY-13315
    Montelukast sodium
    5+ Cited Publications

    MK0476

    Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
    Montelukast sodium
  • HY-13315A
    Montelukast
    5+ Cited Publications

    MK0476 free base

    Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
    Montelukast
  • HY-13315B

    MK0476 dicyclohexylamine

    Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
    Montelukast dicyclohexylamine
  • HY-N2014
    Verbenalin
    1 Publications Verification

    SARS-CoV Infection Inflammation/Immunology
    Verbenalin is Verbena glycoside, with anti-inflammatory, anti-fungal anti-virus activities. Verbenalin can be used for the research of prostatitis. Verbenalin can reduce cerebral ischemia-reperfusion injury .
    Verbenalin
  • HY-117243

    MAP3K Others Cardiovascular Disease
    GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury .
    GSK329
  • HY-108457

    9-Hydroxyphenanthrene; NSC 50554

    TRP Channel Cardiovascular Disease
    9-Phenanthrol (9-Hydroxyphenanthrene) is a potent and selective human TRPM4 inhibitor, with an IC50 of 20 μM. 9-Phenanthrol can be used for the research of ischemia-reperfusion injury .
    9-Phenanthrol
  • HY-E70008

    Sirtuin Inflammation/Immunology
    Lumbokinase attenuates myocardial ischemia-reperfusion (I-R) injury through the activation of Sirt1 signaling, and thus enhances autophagic flux and reduces I-R-induced oxidative damage, inflammation and apoptosis .
    Lumbokinase
  • HY-121726

    mTOR Autophagy Cardiovascular Disease
    3HOI-BA-01 is amTORinhibitor.3HOI-BA-01reduces infarct size and inducedautophagyin a murine myocardial ischemia/reperfusion injury model .
    3HOI-BA-01
  • HY-19121

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    TCV-309 is an antagonist for platelet activating factor (PAF). TCV-309 improves the left ventricular function during ischemia-reperfusion (77.6% recover at 1 μM), protects the cardiac function .
    TCV-309
  • HY-W011082

    NOD-like Receptor (NLR) Cardiovascular Disease
    NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .
    NLRP3-IN-2
  • HY-W841840

    Sirtuin Neurological Disease Cancer
    SR94, a SR17 derivative, is a SIRT2 inhibitor that contains an arbitrary 6-member ring and different R2 groups. SR94 is promising for research of cancer, ischemia-reperfusion and neurodegenerative diseases .
    SR94
  • HY-13315AR

    Leukotriene Receptor Inflammation/Immunology
    Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
    Montelukast (Standard)
  • HY-W015061R

    Adrenergic Receptor Apoptosis Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Phenylacetylglycine (Standard) is the analytical standard of Phenylacetylglycine. This product is intended for research and analytical applications. Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion .
    Phenylacetylglycine (Standard)
  • HY-122935

    HIV Reverse Transcriptase Infection
    Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model .
    Nigranoic acid
  • HY-W015061S

    2-(2-Phenylacetamido)acetic acid-d5

    Adrenergic Receptor Apoptosis Endogenous Metabolite Cardiovascular Disease
    N-(Phenylacetyl-d5)glycine is the deuterium labeled Phenylacetylglycine. Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion[1][2].
    N-(Phenylacetyl-d5)glycine
  • HY-161717

    Adenosine Receptor Cardiovascular Disease
    MRS5663 (Compound 3a) is an A3AR agonist, with an EC50 of 5.62 nM for β-arrestin2 recruitment assay. MRS5663 has a cytoprotective effect on skeletal muscle ischemia-reperfusion injury/claudication model .
    MRS5663
  • HY-101200

    SIN-1 chloride

    Drug Metabolite Cardiovascular Disease
    SIN-1 (chloride) is the active metabolite of molsidomine. SIN-1 (chloride) exhibits potent vasorelaxant effect and inhibition of platelet aggregation . SIN-1 (chloride) decreases myocardial necrosis and reperfusion-induced endothelial dysfunction in models of myocardial ischemia-reperfusion .
    Linsidomine hydrochloride
  • HY-P3199

    PKC Inflammation/Immunology
    PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .
    PKCβII Peptide Inhibitor I
  • HY-10915

    Adenosine Receptor Cardiovascular Disease
    LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury .
    LUF6096
  • HY-N2014R

    SARS-CoV Infection Inflammation/Immunology
    Verbenalin (Standard) is the analytical standard of Verbenalin. This product is intended for research and analytical applications. Verbenalin is Verbena glycoside, with anti-inflammatory, anti-fungal anti-virus activities. Verbenalin can be used for the research of prostatitis. Verbenalin can reduce cerebral ischemia-reperfusion injury .
    Verbenalin (Standard)
  • HY-W033577

    CORM-2

    Others Inflammation/Immunology
    Tricarbonyldichlororuthenium(II) dimer is a pharmacological donor of CO releasing. CO releases from Tricarbonyldichlororuthenium(II) dimer prevents gastric mucosal oxidative damage induced by ischemia/reperfusion (I/R) improving gastric blood flow (GBF), decreasing DNA oxidation and inflammatory response on systemic level .
    Tricarbonyldichlororuthenium(II) dimer
  • HY-111475
    Mitochondrial fusion promoter M1
    1 Publications Verification

    Mitochondrial Metabolism Cardiovascular Disease
    Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury .
    Mitochondrial fusion promoter M1
  • HY-108448

    OLDA

    TRP Channel Cardiovascular Disease
    N-Oleoyldopamine (OLDA) is a product of condensation of oleic acid and dopamine (DA) and an endogenous TRPV1 selective agonist. N-Oleoyldopamine (OLDA) can crosses the blood-brain barrier. N-oleoyl-dopamine protects the heart against ischemia-reperfusion injury via activation of TRPV1 .
    N-Oleoyldopamine
  • HY-W016733

    H-D-Cit-OH

    Endogenous Metabolite Cardiovascular Disease
    D-Citrulline (H-D-Cit-OH) is a stereoisomer of L-citrulline (HY-N0391). D-Citrulline significantly attenuates polymorphonuclear leukocyte (PMN)-induced cardiac contractile dysfunction in the isolated perfused rat heart subjected to ischemia/reperfusion via a non-NO-mediated mechanism .
    D-Citrulline
  • HY-125773

    Beta-cyano-l-alanine

    Endogenous Metabolite Neurological Disease
    β-cyano-L-Alanine (Beta-cyano-l-alanine), a nitrile of widespread occurrence in higher plants, is enzymatically produced by cyanoalanine synthase from cyanide and cysteine as substrates . β-cyano-L-Alanine abolishes the protective effect of ethanol on cerebral ischemia/reperfusion (I/R) injury .
    β-cyano-L-Alanine
  • HY-N6996

    Autophagy PI3K mTOR Akt Inflammation/Immunology Cancer
    Methyl Eugenol is a bait that has oral activity against oriental fruit fly (Hendel).Methyl Eugenol has anti-cancer and anti-inflammatory activities. Methyl Eugenol can induce Autophagy in cells. Methyl Eugenol can be used in the study of intestinal ischemia/reperfusion injury .
    Methyl Eugenol
  • HY-149586

    Reactive Oxygen Species Others
    ROS-IN-2 (compound 85) is a seco-lupane triterpenoid derivative. ROS-IN-2 blocks ROS production and protects mitochondria from damage by inhibiting excessive production of oxidative stressors. ROS-IN-2 can be used for myocardial ischemia/reperfusion (MI/R) injury research .
    ROS-IN-2
  • HY-N0349
    Methyl paraben
    2 Publications Verification

    Methyl 4-hydroxybenzoate

    Bacterial Endogenous Metabolite Infection Inflammation/Immunology
    Methyl Paraben is a standardized methyl paraben allergen isolated from Yunnan hemlock (Tsuga dumosa). Methyl Paraben is commonly used as a stable, non-volatile preservative. Methyl Paraben increases histamine release and cellular regulation of immunity, blocks sodium channels, and prevents ischemia-reperfusion injury .
    Methyl paraben
  • HY-139397
    TJ-M2010-5
    10+ Cited Publications

    MyD88 Cardiovascular Disease
    TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway . TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI) .
    TJ-M2010-5
  • HY-134221

    Others Cardiovascular Disease
    S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis .
    S-Nitroso-N-acetylcysteine
  • HY-13315S1

    MK0476-d6

    Leukotriene Receptor Inflammation/Immunology
    Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
    Montelukast-d6 sodium
  • HY-13315S

    MK0476-d6 free acid

    Isotope-Labeled Compounds Leukotriene Receptor Inflammation/Immunology
    Montelukast-d6 is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
    Montelukast-d6
  • HY-N0745

    Caspase Inflammation/Immunology
    Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3 .
    Senkyunolide I
  • HY-119152

    Insulin Receptor Tyrosinase Akt Others
    CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model .
    CMX-2043
  • HY-117356B

    P2Y Receptor NF-κB ERK Cardiovascular Disease
    MRS2693 trisodium is a selective P2Y6 agonist with an EC50 value of 0.015 μM. MRS2693 trisodium can reduce the activation of NF-kappaB and activate the ERK1/2 pathway, and has a cytoprotective effect on mouse hindlimb skeletal muscle ischemia-reperfusion injury model .
    MRS2693 trisodium
  • HY-135430

    Ferroptosis Inflammation/Immunology
    SRS16-86 is a potent inhibitor of ferroptosis . SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research .
    SRS16-86
  • HY-164304

    Pyroptosis Interleukin Related NOD-like Receptor (NLR) Cardiovascular Disease Inflammation/Immunology
    INF 195 is an NLRP3 inhibitor. INF 195 can inhibit NLRP3 driven macrophage pyroptosis and IL-1β release, with an EC50 value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury .
    INF 195
  • HY-101200R

    Drug Metabolite Cardiovascular Disease
    Linsidomine (hydrochloride) (Standard) is the analytical standard of Linsidomine (hydrochloride). This product is intended for research and analytical applications. SIN-1 (chloride) is the active metabolite of molsidomine. SIN-1 (chloride) exhibits potent vasorelaxant effect and inhibition of platelet aggregation . SIN-1 (chloride) decreases myocardial necrosis and reperfusion-induced endothelial dysfunction in models of myocardial ischemia-reperfusion .
    Linsidomine hydrochloride (Standard)
  • HY-18754

    p38 MAPK Autophagy Endocrinology
    FR 167653 free base, an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 free base is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .
    FR 167653 free base
  • HY-103445

    Elastase Cardiovascular Disease
    SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury . SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases .
    SSR69071

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: